Media

Orexo announces new US patent for ZUBSOLV®

Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)

Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma

Positive results show that C21 can become an important complement to COVID-19 vaccines

BONESUPPORT moves to Mid Cap

Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes

Vicore Pharma announces Last Patient Last Visit in the mechanistic phase II study with C21 in systemic sclerosis

Fusion Pharmaceuticals Initiates Multi-Dose Portion Of Phase 1 Trial Of FPI-1434 In Patients With Advanced Solid Tumors

GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine

Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology